GlassScriptPhysician profile
Mona L Smith
NPI 1164083259
$498.90
in general payments reported to CMS, 2019-2025
11 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.10 · 2023: $37.05 · 2024: $29.96 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.42 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $101.25 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $64.69 | 2025 | Breztri, Farxiga |
| Lilly USA, LLC | $60.10 | 2023-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $46.40 | 2025 | |
| Exact Sciences Corporation | $23.22 | 2025 | The Cologuard Plus Collection Kit |
| Biogen, INC. | $23.00 | 2025 | Zurzuvae |
| Otsuka America Pharmaceutical, INC. | $20.95 | 2023 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $19.06 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $17.71 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $17.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.